Medtech

Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.

Retrieved on: 
Wednesday, April 10, 2024
Wealth, Aix-en-Provence, TP ICAP, TP, Ticker, Medtech, Security (finance)

Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
  • Aix-en-Provence, 4 April 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Gilbert Dupont – Société Générale Group has initiated coverage of its stock.
  • Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024.
  • In this study, Gilbert Dupont – Société Générale Group recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024.

Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.

Retrieved on: 
Wednesday, April 10, 2024
TP, Wealth, Aix-en-Provence, Ticker, Medtech

Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
  • Aix-en-Provence, 28 March 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that TP ICAP Midcap has initiated coverage of its stock.
  • TP ICAP Midcap began covering the stock with a study entitled "Du baume au coeur" ("Heart-Warming"), published on 27 March 2024.
  • This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, and Portzamparc BNP Paribas Group.

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
Partnership, T1D, Medtech, Conference, Immunotherapy, Pharmaceutical industry

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m.

Key Points: 
  • Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m.
  • ET.
  • The company will also participate in virtual 1:1 meetings, and a replay of Mr. Reich’s presentation will be archived on the company website for up to one year.
  • Mr. Reich’s presentation is entitled, “Human Anti Thymocyte Biologic Developed to Delay Onset or Progression of Type 1 Diabetes.” This fully virtual conference will feature fireside chats and presentations from leading public and private companies in the biopharma, medtech, diagnostics and digital health sectors as well as thematic panel discussions.

BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs

Retrieved on: 
Wednesday, April 3, 2024
MagForce, Computer science, University Medical Center, Gesellschaft mit beschränkter Haftung, University, Doctor of Philosophy, Medtech, Quality management, Quality, Heart, CSO, ISO, Nursing

Leipzig, Germany, April 3, 2024 – BellaSeno GmbH , an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.

Key Points: 
  • Leipzig, Germany, April 3, 2024 – BellaSeno GmbH , an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.
  • Inga Freyert served as BellaSeno´s Head of Quality Management since 2022 and was promoted to VP Quality Management and Regulatory Affairs in early 2024.
  • Before joining bess pro GmbH, Inga Freyert worked as Quality & Regulatory Specialist / Junior Q&R Manager at MagForce AG, Berlin.
  • “We warmly welcome Dr. Thomas Lingner and Inga Freyert to their new roles at BellaSeno,” said Dr. Mohit Chhaya, CEO of BellaSeno.

Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC

Retrieved on: 
Wednesday, April 3, 2024
University of London, University, Public health, Growth, Health, Patient, Business development, Columbia University, Head, L.E.K. Consulting, MBA, Medtech, Master, MPH, Partner, SOAS

Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan pharmaceutical sector expert, Mr. Patrick Branch, as Head of Business Development for Japan and the APAC region.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan pharmaceutical sector expert, Mr. Patrick Branch, as Head of Business Development for Japan and the APAC region.
  • Branch will join Nxera’s global Business Development team that is led by Dr. Marcus Messenger.
  • He will be based in Nxera’s Tokyo office and will oversee Japan and regional disease area strategy, search and evaluation, and transaction activities.
  • Chris Cargill, CEO and President of Nxera Pharma, commented: “I’m delighted to welcome Patrick to the business development team at Nxera.

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Retrieved on: 
Monday, April 1, 2024
Burn, Brigham Young University, Avita Medical, MDAI, Business administration, Patient, Global strategy, Artificial intelligence, Spectral, Publication, Master of Business Administration, Health Economics, Johnson & Johnson, Allergan, Government, Physician, Medtech

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.

Key Points: 
  • DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.
  • Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.
  • Mr. Sparks will be responsible for both domestic and international product commercialization.
  • “We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter M. Carlson, CEO of Spectral AI.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

LogiPharma 2024 Playbook Highlights Why Real-Time Visibility & Data are Critical to Ensuring the Quality & Safety of New Medicines & Patient Therapies

Retrieved on: 
Tuesday, March 26, 2024
Automation, Temperature, Agility, Risk management, Research, Cold chain, Playbook, Johnson & Johnson, Artificial intelligence, Medtech, Fine chemical

The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.

Key Points: 
  • The Playbook includes a detailed examination by Alex Guillen, Tive's Global SME in Life Sciences and Pharma, on the role of precise and timely supply chain data.
  • Guillen believes that ensuring the successful delivery and launch of dozens of new cell and gene therapies, as expected in 2024, is fundamentally dependent on the industry’s advancements in real-time supply chain visibility.
  • “An essential part of the conversation for pharma leaders today is how to address the critical challenges of modern therapy delivery," said Guillen.
  • To learn more about Tive and LogiPharma 2024, please visit www.tive.com and www.logipharmaeu.com .

Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Other Retail, Health, Retail, Pharmaceutical, Webcast, Conference, JNJ, Eastern Time Zone, Medtech, Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York.
  • Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240408576293/en/

John Witkowski Appointed President & CEO of Solesis

Retrieved on: 
Monday, April 8, 2024
Health, Chemicals, Plastics, Medical Devices, Manufacturing, Pharmaceutical, Textiles, Biotechnology, Growth, Patient, Bemis Manufacturing Company, Quality, Multimedia, CMS, Medtech, Development, Management

Solesis, a leader in the custom design, development, and manufacturing of textile- and polymer-based healthcare solutions for the medical device and biopharmaceutical industries, is pleased to announce that John Witkowski has been appointed as the new President & CEO, effective immediately.

Key Points: 
  • Solesis, a leader in the custom design, development, and manufacturing of textile- and polymer-based healthcare solutions for the medical device and biopharmaceutical industries, is pleased to announce that John Witkowski has been appointed as the new President & CEO, effective immediately.
  • In this role, Witkowski is responsible for developing the strategic priorities for Solesis and executing world-class business operations to support customers and drive long-term, sustainable growth.
  • View the full release here: https://www.businesswire.com/news/home/20240408466371/en/
    John Witkowski has been appointed as the new President & CEO of Solesis.
  • “Joining a leader in the MedTech and Biopharma industries is exciting, especially when coupled with a period of growth like Solesis is currently experiencing,” said John Witkowski, President & CEO of Solesis.